Published in Arch Dermatol on September 01, 1998
Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol (2014) 1.47
A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol (2014) 0.92
Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol (1998) 0.87
Specific causes of death in patients with bullous pemphigoid as measured by death certificate data: a retrospective cohort study. Int J Dermatol (2013) 0.86
Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay. J Am Acad Dermatol (2012) 0.79
Advances in understanding and managing bullous pemphigoid. F1000Res (2015) 0.75
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep (2015) 0.75
[Bullous pemphigoid revealing bronchial carcinoma]. Pan Afr Med J (2014) 0.75
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol (1993) 5.51
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst (1999) 5.15
Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg (1996) 5.05
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol (2007) 4.61
Apolipoprotein E polymorphism and Alzheimer's disease. Lancet (1993) 4.47
Identification and characterization of Saccharomyces cerevisiae EXO1, a gene encoding an exonuclease that interacts with MSH2. Proc Natl Acad Sci U S A (1997) 3.66
Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol (2001) 3.41
Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol (1991) 3.29
Problems performing a sciatic nerve block in an amputee. Anaesthesia (2003) 3.23
SIV adaptation to human cells. Nature (1989) 3.09
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol (2000) 3.06
Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med (1988) 3.03
Cloning and expression of a cardiac/brain beta subunit of the L-type calcium channel. J Biol Chem (1992) 3.03
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 2.89
Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology (1977) 2.79
Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol (2000) 2.67
Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. A prospective study. Arch Intern Med (1997) 2.63
Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med (1992) 2.54
Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol (2013) 2.38
Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol (1995) 2.37
Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34
HSV-1 in brain and risk of Alzheimer's disease. Lancet (1998) 2.21
Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis (1988) 2.19
Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol (1995) 2.16
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS (2001) 2.12
Lon-dependent proteolysis of CcdA is the key control for activation of CcdB in plasmid-free segregant bacteria. Mol Microbiol (1994) 2.02
Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol (1992) 2.01
[Drug surveillance and topical drugs]. Ann Dermatol Venereol (1996) 2.01
[Survey of post-graduate training for Dermatology and Venereology residents in France (2005-2010)]. Ann Dermatol Venereol (2013) 2.00
Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol (1995) 1.98
Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96
New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM). Science (1986) 1.91
Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A (1995) 1.91
ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther (2010) 1.83
Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ (1999) 1.79
Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol (1999) 1.77
The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. J Antimicrob Chemother (2008) 1.75
Modelling age-specific risk: application to dementia. Stat Med (1998) 1.74
The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol (1987) 1.69
[Malignant ethmoid bone tumors in woodworkers]. J Med Lyon (1969) 1.68
Calcifying fibrous pseudotumour: first case report in the peritoneum with immunostaining for CD34. Histopathology (1999) 1.63
Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol (1987) 1.62
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol (2013) 1.60
Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn (1995) 1.59
Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest (1986) 1.57
Churg-Strauss angiitis. Arguments favoring the responsibility of inhaled antigens. Chest (1991) 1.55
Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol (2015) 1.55
Double-blind, randomized trial of diazepam versus placebo for prevention of recurrence of febrile seizures. J Pediatr (1990) 1.53
Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol (1993) 1.52
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leuk Res (1997) 1.50
Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol (1987) 1.45
[Complication of radical lymph node dissection following sentinel lymph node biopsy in patients with melanoma]. Ann Dermatol Venereol (2013) 1.44
Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol (1995) 1.43
Clinical and histological features of head and neck melanoma: a population-based study in France. Br J Dermatol (2015) 1.42
Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis. Br J Dermatol (1994) 1.42
Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol (2001) 1.42
Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr (1994) 1.42
[Does bullous pemphigoid with negative direct immunofluorescence exist? Apropos of 3 cases]. Ann Dermatol Venereol (1992) 1.40
Hypothermia related to air-fluidized bed. Intensive Care Med (1991) 1.39
Adult onset Still's disease and pregnancy. J Rheumatol (1993) 1.39
[Eosinophilic dermatosis associated with hematological disorders: A clinical, histopathological and immunohistochemical study of six observations]. Ann Dermatol Venereol (2010) 1.39
Role of drug exposure in aphthous ulcers: a case-control study. Br J Dermatol (2000) 1.39
Increased prevalence of psoriasis in patients with coronary artery disease: results from a case-control study. Br J Dermatol (2014) 1.39
The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. Br J Dermatol (2012) 1.39
[Contact vasculitis caused by topical agents with non-steroidal anti-inflammatory agents or analgesics]. Ann Dermatol Venereol (1997) 1.38
Cloxacillin versus pristinamycin for superficial pyodermas: a randomized, open-label, non-inferiority study. Dermatology (2005) 1.38
[Haemorrhagic cellulitis: three cases]. Ann Dermatol Venereol (2003) 1.38
Possible association of erythema multiforme with acamprosate. Lancet (1992) 1.37
Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia (1997) 1.36
Molecular cloning of a novel splice variant of the alpha subunit of the mammalian Go protein. J Biol Chem (1990) 1.36
Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer (1996) 1.36
Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis (1996) 1.34
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol (2009) 1.32
A new concept in Dorello's canal microanatomy: the petroclival venous confluence. J Neurosurg (1997) 1.31
Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer (2000) 1.29
Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry (1991) 1.29
Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol (2001) 1.28
A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry (1994) 1.28
MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res (2001) 1.28
Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol (1996) 1.28
Severe cutaneous reactions to self-defense sprays. Arch Dermatol (1993) 1.28
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol (1996) 1.27
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol (2013) 1.27
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood (2000) 1.27
Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol (2012) 1.26
[3Fe-4S] to [4Fe-4S] cluster conversion in Desulfovibrio fructosovorans [NiFe] hydrogenase by site-directed mutagenesis. Proc Natl Acad Sci U S A (1998) 1.25